Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Prognostic significance of corticotroph staining in radiosurgery for non-functioning pituitary adenomas: a multicenter study

O. Cohen-Inbar, Z. Xu, CC. Lee, CC. Wu, T. Chytka, D. Silva, M. Sharma, H. Radwan, IS. Grills, B. Nguyen, Z. Siddiqui, D. Mathieu, C. Iorio-Morin, A. Wolf, CP. Cifarelli, DT. Cifarelli, LD. Lunsford, D. Kondziolka, JP. Sheehan,

. 2017 ; 135 (1) : 67-74. [pub] 20170914

Language English Country United States

Document type Journal Article, Multicenter Study

Persistent link   https://www.medvik.cz/link/bmc18024641
E-resources Online Full text

NLK ProQuest Central from 1997-01-01 to 1 year ago
Medline Complete (EBSCOhost) from 2009-07-01 to 1 year ago
Health & Medicine (ProQuest) from 1997-01-01 to 1 year ago
Public Health Database (ProQuest) from 1997-01-01 to 1 year ago

Links

PubMed 28913674
DOI 10.1007/s11060-017-2520-y
Knihovny.cz E-resources

Silent corticotroph staining pituitary adenoma (SCA) represents an uncommon subset of Non-Functioning adenomas (NFAs), hypothesized to be more locally aggressive. In this retrospective multicenter study, we investigate the safety and effectiveness of Stereotactic Radiosurgery (SRS) in patients with SCA compared with other non-SCA NFA's. Eight centers participating in the International Gamma-Knife Research Foundation (IGKRF) contributed to this study. Outcomes of 50 patients with confirmed SCAs and 307 patients with confirmed non-SCA NFA's treated with SRS were evaluated. Groups were matched. SCA was characterized by a lack of clinical evidence of Cushing disease, yet with positive immunostaining for corticotroph. Median age was 55.2 years (13.7-87). All patients underwent at least one trans-sphenoidal tumor resection prior to SRS. SRS parameters were comparable as well. Median follow-up 40 months (6-163). Overall tumor control rate (TCR) 91.2% (n = 280). In the SCA group, TCR were 82% (n = 41) versus 94.1% (n = 289) for the control-NFA (p = 0.0065). The SCA group showed a significantly higher incidence of new post-SRS visual deficit (p < 0.0001) assigned to tumor progression and growth, and post-SRS weakness and fatigue (p < 0.0001). In univariate and multivariate analysis, only the status of silent corticotroph staining (p = 0.005, p = 0.009 respectively) and margin dose (p < 0.0005, p = 0.0037 respectively) significantly influenced progression rate. A margin dose of ≥17 Gy was noted to influence the adenoma progression rate in the entire cohort (p = 0.003). Silent corticotroph staining represents an independent factor for adenoma progression and hypopituitarism after SRS. A higher margin dose may convey a greater chance of TCR.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18024641
003      
CZ-PrNML
005      
20180717100606.0
007      
ta
008      
180709s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s11060-017-2520-y $2 doi
035    __
$a (PubMed)28913674
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Cohen-Inbar, Or $u Department of Neurosurgery, University of Virginia, Charlottesville, VA, USA. oc2f@virginia.edu. Department of Neurological Surgery, University of Virginia, Charlottesville, VA, 22908, USA. oc2f@virginia.edu.
245    10
$a Prognostic significance of corticotroph staining in radiosurgery for non-functioning pituitary adenomas: a multicenter study / $c O. Cohen-Inbar, Z. Xu, CC. Lee, CC. Wu, T. Chytka, D. Silva, M. Sharma, H. Radwan, IS. Grills, B. Nguyen, Z. Siddiqui, D. Mathieu, C. Iorio-Morin, A. Wolf, CP. Cifarelli, DT. Cifarelli, LD. Lunsford, D. Kondziolka, JP. Sheehan,
520    9_
$a Silent corticotroph staining pituitary adenoma (SCA) represents an uncommon subset of Non-Functioning adenomas (NFAs), hypothesized to be more locally aggressive. In this retrospective multicenter study, we investigate the safety and effectiveness of Stereotactic Radiosurgery (SRS) in patients with SCA compared with other non-SCA NFA's. Eight centers participating in the International Gamma-Knife Research Foundation (IGKRF) contributed to this study. Outcomes of 50 patients with confirmed SCAs and 307 patients with confirmed non-SCA NFA's treated with SRS were evaluated. Groups were matched. SCA was characterized by a lack of clinical evidence of Cushing disease, yet with positive immunostaining for corticotroph. Median age was 55.2 years (13.7-87). All patients underwent at least one trans-sphenoidal tumor resection prior to SRS. SRS parameters were comparable as well. Median follow-up 40 months (6-163). Overall tumor control rate (TCR) 91.2% (n = 280). In the SCA group, TCR were 82% (n = 41) versus 94.1% (n = 289) for the control-NFA (p = 0.0065). The SCA group showed a significantly higher incidence of new post-SRS visual deficit (p < 0.0001) assigned to tumor progression and growth, and post-SRS weakness and fatigue (p < 0.0001). In univariate and multivariate analysis, only the status of silent corticotroph staining (p = 0.005, p = 0.009 respectively) and margin dose (p < 0.0005, p = 0.0037 respectively) significantly influenced progression rate. A margin dose of ≥17 Gy was noted to influence the adenoma progression rate in the entire cohort (p = 0.003). Silent corticotroph staining represents an independent factor for adenoma progression and hypopituitarism after SRS. A higher margin dose may convey a greater chance of TCR.
650    _2
$a adenom $x diagnóza $x epidemiologie $x patologie $x chirurgie $7 D000236
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a kortikotropní buňky $x patologie $7 D052680
650    _2
$a progrese nemoci $7 D018450
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a hypopituitarismus $x epidemiologie $7 D007018
650    _2
$a incidence $7 D015994
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a lidé středního věku $7 D008875
650    _2
$a multivariační analýza $7 D015999
650    _2
$a nádory hypofýzy $x diagnóza $x epidemiologie $x patologie $x chirurgie $7 D010911
650    _2
$a pooperační komplikace $x epidemiologie $7 D011183
650    _2
$a prognóza $7 D011379
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Xu, Zhiyuan $u Department of Neurosurgery, University of Virginia, Charlottesville, VA, USA.
700    1_
$a Lee, Cheng-Chia $u Department of Neurosurgery, Neurological Institute, Taipei Veteran General Hospital, Taipei, Taiwan, Republic of China. National Yang-Ming University, Taipei, Taiwan, Republic of China.
700    1_
$a Wu, Chin-Chun $u Department of Radiology, Taipei Veteran General Hospital, Taipei, Taiwan, Republic of China.
700    1_
$a Chytka, Tomáš $u Department of Stereotactic and Radiation Neurosurgery, Na Homolce Hospital, Prague, Czech Republic.
700    1_
$a Silva, Danilo $u Rose-Ella Burkhardt Brain Tumor and Neuro-oncology Center, Cleveland Clinic, Cleveland, OH, USA.
700    1_
$a Sharma, Mayur $u Rose-Ella Burkhardt Brain Tumor and Neuro-oncology Center, Cleveland Clinic, Cleveland, OH, USA.
700    1_
$a Radwan, Hesham $u Rose-Ella Burkhardt Brain Tumor and Neuro-oncology Center, Cleveland Clinic, Cleveland, OH, USA.
700    1_
$a Grills, Inga S $u Department of Radiation Oncology, Beaumont Health System, Royal Oak, MI, USA.
700    1_
$a Nguyen, Brandon $u Department of Radiation Oncology, Beaumont Health System, Royal Oak, MI, USA.
700    1_
$a Siddiqui, Zaid $u Department of Radiation Oncology, Beaumont Health System, Royal Oak, MI, USA.
700    1_
$a Mathieu, David $u Department of Neurosurgery, Centre de Recherche Clinique Étienne-LeBel, University of Sherbrooke, Sherbrooke, QC, Canada.
700    1_
$a Iorio-Morin, Christian $u Department of Neurosurgery, Centre de Recherche Clinique Étienne-LeBel, University of Sherbrooke, Sherbrooke, QC, Canada.
700    1_
$a Wolf, Amparo $u Department of Neurosurgery, New York University Langone Medical Center, New York, NY, USA.
700    1_
$a Cifarelli, Christopher P $u Department of Neurosurgery, West Virginia University, Morgantown, WV, USA.
700    1_
$a Cifarelli, Daniel T $u Department of Anesthesiology, West Virginia University, Morgantown, WV, USA.
700    1_
$a Lunsford, L Dade $u Department of Neurosurgery, University of Pittsburgh, Pittsburgh, PA, USA.
700    1_
$a Kondziolka, Douglas $u Department of Neurosurgery, New York University Langone Medical Center, New York, NY, USA.
700    1_
$a Sheehan, Jason P $u Department of Neurosurgery, University of Virginia, Charlottesville, VA, USA.
773    0_
$w MED00002827 $t Journal of neuro-oncology $x 1573-7373 $g Roč. 135, č. 1 (2017), s. 67-74
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28913674 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20180717100905 $b ABA008
999    __
$a ok $b bmc $g 1316772 $s 1021562
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 135 $c 1 $d 67-74 $e 20170914 $i 1573-7373 $m Journal of neuro-oncology $n J Neurooncol $x MED00002827
LZP    __
$a Pubmed-20180709

Find record

Citation metrics

Archiving options